About Silence Therapeutics plc
https://www.silence-therapeutics.comSilence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver.
CEO
Iain Gladstone Ross
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 10
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Chardan Capital
Buy
BMO Capital
Outperform
Morgan Stanley
Overweight
Goldman Sachs
Sell
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
TCG CROSSOVER MANAGEMENT, LLC
Shares:3.03M
Value:$17.81M
SIREN, L.L.C.
Shares:2.91M
Value:$17.09M
REDMILE GROUP, LLC
Shares:2.16M
Value:$12.71M
Summary
Showing Top 3 of 56
About Silence Therapeutics plc
https://www.silence-therapeutics.comSilence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $159K ▼ | $26.34M ▲ | $-20.96M ▲ | -13.18K% ▼ | $-1.32 ▲ | $-20.8M ▲ |
| Q2-2025 | $224K ▲ | $24.1M ▼ | $-27.35M ▲ | -12.21K% ▲ | $-1.74 ▲ | $-22.49M ▲ |
| Q1-2025 | $142K ▼ | $28.5M ▲ | $-28.53M ▼ | -20.09K% ▼ | $-1.8 ▼ | $-28.27M ▼ |
| Q4-2024 | $24.33M ▲ | $25.8M ▲ | $14.17M ▲ | 58.26% ▲ | $0.9 ▲ | $7.19M ▲ |
| Q3-2024 | $1.14M | $20.91M | $-27.01M | -2.37K% | $-1.71 | $-21.44M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $102.19M ▼ | $146.79M ▼ | $72.73M ▲ | $74.06M ▼ |
| Q2-2025 | $114.16M ▼ | $165.23M ▼ | $71.08M ▼ | $94.16M ▲ |
| Q1-2025 | $136.53M ▼ | $185.3M ▼ | $298.04M ▲ | $-112.74M ▼ |
| Q4-2024 | $147.33M ▲ | $202.63M ▲ | $68.61M ▼ | $134.02M ▲ |
| Q3-2024 | $128.99M | $169.38M | $74.87M | $94.52M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-20.96M ▲ | $-10.89M ▲ | $51.29M ▲ | $0 ▼ | $40.29M ▲ | $-10.89M ▲ |
| Q2-2025 | $-27.35M ▼ | $-21.78M ▼ | $-1.56M ▲ | $1K ▼ | $-23.15M ▲ | $-21.83M ▼ |
| Q1-2025 | $-22.08M ▼ | $-12.31M ▲ | $-44.38M ▼ | $14K ▼ | $-56.44M ▼ | $-12.31M ▲ |
| Q4-2024 | $22.89M ▲ | $-24.86M ▼ | $68.13M ▲ | $19.88M ▲ | $59.38M ▲ | $-24.92M ▼ |
| Q3-2024 | $-41.88M | $-19.66M | $-28.84M | $5.97M | $-47.53M | $-19.7M |
Revenue by Products
| Product | Q1-2025 | Q2-2025 |
|---|---|---|
 Research Collaboration Income | $0 ▲ | $0 ▲ |
CEO
Iain Gladstone Ross
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 10
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Chardan Capital
Buy
BMO Capital
Outperform
Morgan Stanley
Overweight
Goldman Sachs
Sell
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
TCG CROSSOVER MANAGEMENT, LLC
Shares:3.03M
Value:$17.81M
SIREN, L.L.C.
Shares:2.91M
Value:$17.09M
REDMILE GROUP, LLC
Shares:2.16M
Value:$12.71M
Summary
Showing Top 3 of 56